IGF-1 DES
Truncated IGF-1 Analog · Localized Muscle Growth
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
Overview
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.
Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
Accelerates local tissue recovery in the injected muscle group after training.
Promotes repair and regeneration at the injection site through IGF-1R activation.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Truncated IGF-1 analog
- Chain length
- 67 residues
- Molecular weight
- 7000 Da
- Half-life
- ~25 min
- Typical dose
- 20-50mcg post-workout (site-specific IM injection)
- Frequency
- Post-workout only, injected into trained muscle
- Cycle length
- 4-6 weeks maximum
- Storage
- Lyophilized: -20C. Reconstituted: 2-8C, use within 7 days (BAC water)
Molecular data
- Type
- Truncated IGF-1 analog
- Molecular weight
- 7000 Da
- Chain length
- 67 residues
- Half-life
- 25 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Beginner Protocol | IM (site-specific) | 20-30mcg | Post-workout, injected into trained muscle |
| Intermediate | IM (site-specific) | 30-50mcg | Post-workout, injected into trained muscle |
| Advanced | IM (site-specific) | 50mcg | Post-workout, split across multiple trained muscles |
Interactions
HGH raises baseline IGF-1 levels; adding IGF-1 DES post-workout provides a localized anabolic spike on top of elevated systemic IGF-1. Use with caution and monitor blood glucose.
Do not stack with IGF-1 DES. Both are IGF-1 analogs acting on the same receptor. Choose one or the other based on whether you want systemic (LR3) or localized (DES) effects.
Testosterone increases IGF-1 receptor density and satellite cell number, amplifying the local effects of IGF-1 DES at the injection site.
Both lower blood glucose. Combining IGF-1 DES with exogenous insulin significantly increases hypoglycemia risk.
Quality checklist
- ✓HPLC purity >95%
- ✓Mass spectrometry confirmation of truncated sequence
- ✓Cold storage maintained (-20C lyophilized)
- ✓Certificate of analysis from reputable source
- !Research chemical only -- never approved for human use
- !No human clinical trials exist
- !Extremely short half-life requires precise timing
- ×Hypoglycemia risk -- blood sugar can drop rapidly after injection
- ×Potential for disproportionate muscle growth with repeated site-specific use
- ×Black market quality varies -- degraded product is common
- ×Cancer proliferation concern -- elevated IGF-1 activity promotes cell growth
What to expect
Safety
- Hypoglycemia -- consume carbohydrates after injection
- Localized swelling and soreness at injection site
- Increased pump in targeted muscles
- Mild lightheadedness shortly after injection
- Severe or recurring hypoglycemia despite carbohydrate intake
- Disproportionate or asymmetric muscle growth
- Unusual growths, lumps, or rapid mole changes
- Persistent pain, redness, or infection at injection site
- Signs of systemic IGF-1 excess (jaw growth, organ enlargement)
- Not approved for human use -- research chemical only
- Cancer history or active malignancy (IGF-1 promotes cell proliferation)
- Diabetes or impaired glucose regulation
- WADA prohibited substance -- causes failed drug tests
FAQ
Why is IGF-1 DES injected directly into muscles?
IGF-1 DES has a 20-30 minute half-life and doesn't bind IGF binding proteins, making it 10x more potent but short-acting. Direct intramuscular injection confines its activity to the targeted muscle immediately post-workout, enabling localized hypertrophy without systemic IGF-1 excess.
Will IGF-1 DES cause hypoglycemia?
Yes. IGF-1 DES lowers blood glucose by promoting glucose uptake into muscle tissue. You must consume 20-40g of fast carbohydrates immediately after injection. Monitor blood glucose early in use and never inject before sleep due to overnight hypoglycemia risk.
Can I use IGF-1 DES if I'm on a keto diet?
Not safely. The mandatory carbohydrate intake after IGF-1 DES injection will break ketosis. If keto is your goal, use alternatives like GH or ipamorelin instead. The post-injection carbs are non-negotiable for safety.
Does IGF-1 DES cause cancer risk?
IGF-1 promotes cell proliferation, and elevated systemic IGF-1 is linked to multiple cancers in the UK Biobank study. DES minimizes systemic exposure through its short half-life and local injection, but cancer risk remains a theoretical concern with any IGF-1 product.
References
- 1The isolation and characterization of a naturally occurring truncated form of IGF-I in human brainSara VR, Carlsson-Skwirut C, Andersson C, Hall E, Sjogren B, Holmgren A, Jornvall H · Biochemical and Biophysical Research Communications · 1986
First identification and characterization of Des(1-3) IGF-1 as a naturally occurring truncated form of IGF-1 in human brain tissue, establishing that the N-terminal tripeptide deletion occurs endogenously.
reviewPubMed 3753607 ↗ - 2Des(1-3)IGF-I: A truncated form of insulin-like growth factor-I that has greatly enhanced activity in promoting growthFrancis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR · Journal of Molecular Endocrinology · 1992
Des(1-3) IGF-1 demonstrated approximately 10-fold greater potency than intact IGF-1 in stimulating protein synthesis and cell proliferation, directly attributable to its inability to bind IGF binding proteins.
reviewPubMed 1381175 ↗ - 3Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated ratsTomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ · Biochemical Journal · 1992
Des(1-3) IGF-1 and LR3-IGF-1 were significantly more potent than native IGF-1 in reversing dexamethasone-induced muscle wasting in rats, with truncated and modified variants showing superior anabolic activity.
animalPubMed 1371669 ↗ - 4Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK BiobankMurphy N, Knuppel A, Papadimitriou N, Martin RM, Tsilidis KK, Brennan P et al. · Cancer Research · 2020
Higher circulating IGF-1 associated with increased risks of colorectal, breast, prostate, and thyroid cancers in >395,000 UK Biobank participants, underscoring the cancer risk of sustained IGF-1 pathway activation.
reviewPubMed 32709735 ↗